Investigating risk factors and potential drugs for recurrent liver cancer after surgery
Risk Factors, Prognosis, and Potential Chemoprevention Drugs in Patients With Recurrent Hepatocellular Carcinoma After Curative Surgeries: a Nationwide Retrospective Cohort Study and a Multi-center Prospective Cohort Analysis
This study is trying to find out what causes liver cancer to come back after surgery and see if certain drugs can help prevent it for people who have had hepatocellular carcinoma.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 20 Years and up |
| Sex | All |
| Sponsor | China Medical University Hospital Academic / other |
| Locations | 1 site (Taichung) |
| Trial ID | NCT05990959 on ClinicalTrials.gov |
What this trial studies
This study aims to analyze risk factors and prognosis for patients with recurrent hepatocellular carcinoma (HCC) following curative surgeries through a nationwide retrospective cohort and a multicenter prospective cohort analysis. It will utilize a comprehensive database to establish prediction models and identify potential chemoprevention agents that may reduce the risk of recurrence. Additionally, the study will create a shared platform for collecting biological materials and clinical information from multiple hospitals to validate and enhance the prediction models. The research will also include laboratory studies to explore the relationship between biomarkers and HCC prognosis.
Who should consider this trial
Good fit: Ideal candidates for this study are surgical patients aged over 20 who have undergone surgery for hepatocellular carcinoma and are willing to donate remnant tissue or blood.
Not a fit: Patients who are pregnant or do not meet the inclusion criteria will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved prediction of HCC recurrence and the identification of effective chemoprevention strategies for patients.
How similar studies have performed: While there have been studies on HCC recurrence, this approach of integrating nationwide data with multicenter collaboration for biomarker discovery is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * All HCC surgical patients aged more than 20 year-old who sign informed consent for donating remnant tissue or blood after liver surgeries Exclusion Criteria: * Pregnant women
Where this trial is running
Taichung
- China Medical University Hospital, Department of Surgery — Taichung, Taiwan (Recruiting)
Study contacts
- Principal investigator: Chun-Chieh Yeh, Dr. — China Medical University Hospital,Taiwan
- Study coordinator: Chun-Chieh Yeh, Dr.
- Email: Transplantyeh@gmail.com
- Phone: 886975681449
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.